AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04161547
Drug: CSPCHA115 100 mg; Matching placebo 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
Trial: NCT04161547
Drug: CSPCHA115 200 mg; Matching placebo 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
Trial: NCT04161547
Drug: CSPCHA115 400 mg; Matching placebo 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
Trial: NCT04161547
Drug: CSPCHA115 600 mg; Matching placebo 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
Trial: NCT02213926
Drug: ACP-196 (acalabrutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00836914
Drug: CAL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
Trial: NCT00836914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules administered orally BID for 7 days
Trial: NCT03284593
Drug: intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00804414
Drug: SBG
RxNorm normalized name: PSBG - Pregnancy specific beta 1-glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for topical use
Trial: NCT00804414
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solutin for topical use
Trial: NCT02057302
Drug: Xuezhikang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01196104
Drug: Technosphere® Insulin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01720797
Drug: Anesthestic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
Trial: NCT01654822
Drug: topical application cervical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
Trial: NCT00585559
Drug: Placebos for acetaminophen and N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos for acetaminophen and N-acetylcysteine
Trial: NCT00585559
Drug: APAP 1 gm every 6 hours and N-acetylcysteine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
Trial: NCT00585559
Drug: NAC IV infusion at 0.5 gm hourly and APAP placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
Trial: NCT00585559
Drug: APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Trial: NCT03852160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo as nasal spray.
Trial: NCT00585559
Drug: APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Trial: NCT00264472
Drug: ADH300004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg
Trial: NCT06027775
Drug: Targeted agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
Trial: NCT03814746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
Trial: NCT01723514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once a month
Trial: NCT00979745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 16mg subcutaneous implant every 2 months for 9 months.
Trial: NCT03657537
Drug: Ketone infusion
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-hydroxybutyrate is infused intravenously.
Trial: NCT03657537
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline is infused intravenously.
Trial: NCT03709316
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Trial: NCT01845558
Drug: Wobenzym® plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01747629
Drug: Placebo MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Trial: NCT01544309
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)
Trial: NCT00741351
Drug: Sevoflurane + Fentanyl
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
Trial: NCT00741351
Drug: Sevoflurane + Remifentanyl
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
Trial: NCT00741351
Drug: Propofol + Remifentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
Trial: NCT01544491
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
Trial: NCT00780442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00570258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 150 mg PO QD
Trial: NCT00181532
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01196247
Drug: Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved drugs as indicated by molecular profiling
Trial: NCT00291863
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03716583
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg
Trial: NCT04656652
Drug: DS-1062a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
Trial: NCT03716583
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g
Trial: NCT01102387
Drug: LAS41003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topically
Trial: NCT01102387
Drug: LAS189962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topically
Trial: NCT01102387
Drug: LAS189961
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topically
Trial: NCT01114698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
Trial: NCT01114698
Drug: JNJ26489112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
Trial: NCT04266093
Drug: GeneTherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation/ Gene Therapy Long-term Follow-up. Subjects who have enrolled on an applicable NCI CIO gene therapy treatment protocol.
Trial: NCT00657475
Drug: Heparin Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
Trial: NCT00657475
Drug: Heparin Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
Trial: NCT04137302
Drug: Hydrocortisone administration
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
Trial: NCT01586533
Drug: Zoenasa-1:4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
Trial: NCT01586533
Drug: Mesalamine Enema
RxNorm normalized name: mesalamine Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
Trial: NCT00729053
Drug: IMO-2055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunostimulatory oligonucleotide
Trial: NCT02306161
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02306161
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02306161
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00945178
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, single oral dose, 500mg
Trial: NCT04606381
Drug: Ami-HC-CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
Trial: NCT03300609
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03300609
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03300609
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03698630
Drug: Prednisolone Sodium Phosphate
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
Trial: NCT04200404
Drug: CS1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
Trial: NCT00848393
Drug: Fentanyl (High Dose)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
Trial: NCT00848393
Drug: Fentanyl (Low Dose)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
Trial: NCT00848393
Drug: Fentanyl (Low Dose) + Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
Trial: NCT01935596
Drug: ropivacaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal anesthesia.
Trial: NCT01935596
Drug: lévobupivacaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01750086
Drug: Alendronate Oral Tablet
RxNorm normalized name: alendronate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly alendronate for 8 weeks
Trial: NCT00003133
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04252300
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
Trial: NCT04252300
Drug: Rosuvastatin + BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
Trial: NCT00443898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle (placebo) applied once daily for 48 weeks
Trial: NCT00443898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle (placebo) applied once daily for 24 weeks
Trial: NCT04163835
Drug: 1/2 Normal-dose Wenxin Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g.
Trial: NCT04163835
Drug: Twice Normal-dose Wenxin Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g.
Trial: NCT04163835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g.
Trial: NCT00555646
Drug: PH-10 (rose bengal disodium 0.001%)
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
Trial: NCT00555646
Drug: PH-10 (rose bengal disodium 0.001%)
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment plaque area 2: PH-10 with ambient light illumination.
Trial: NCT02289716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Trial: NCT03245762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 IU/day of placebo administered via nasal spray device each morning
Trial: NCT03808259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo.
Trial: NCT02511106
Drug: AZD9291 80 mg/40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Trial: NCT02511106
Drug: Placebo AZD9291 80 mg/40 mg
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Trial: NCT01501747
Drug: Caffeine, paracetamol, cephalexin, or ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
Trial: NCT00024570
Drug: IL13-PE38QQR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00529555
Drug: minocycline HCl 2.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
Trial: NCT02639078
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dosing in capsule formulation
Trial: NCT02723383
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
Trial: NCT00005797
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
Trial: NCT01364441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosed in the same manner as ONO-2952
Trial: NCT01373333
Drug: 3,4 DAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
Trial: NCT00004403
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04157959
Drug: SHR4640 dose1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet,dose1,QD
Trial: NCT02309463
Drug: Endothelin receptor antagonist therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03036150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching dapagliflozin 10 mg or 5 mg
Trial: NCT00392886
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00392886
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03617016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to domperidone tablets orally.
Trial: NCT03649997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
Trial: NCT01974934
Drug: Desvenlafaxine Succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01349881
Drug: Eflornithine placebo & sulindac placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
Trial: NCT01349881
Drug: eflornithine & sulindac placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
Trial: NCT01349881
Drug: Eflornithine placebo & sulindac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Trial: NCT01349881
Drug: Eflornithine plus sulindac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Trial: NCT02668796
Drug: Estradiol Vaginal Tablets 10 mcg (Glenmark)
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply using the given applicator
Trial: NCT02668796
Drug: Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply using the given applicator
Trial: NCT02668796
Drug: Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply using the given applicator
Trial: NCT04175600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be administered orally.